JF
URGN icon

Jump Financial’s UroGen Pharma URGN Stock Holding History

Jump Financial’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,900
Closed -$419K – 2423
2025
Q4 		$419K Sell
17,900
-85,966
-83% -$1.86M 0.01% 1393
2025
Q3 		$2.07M Buy
+103,866
New +$1.87M 0.02% 714
2025
Q1 		– Sell
-17,185
Closed -$183K – 2044
2024
Q4 		$183K Sell
17,185
-39,265
-70% -$470K ﹤0.01% 1503
2024
Q3 		$717K Buy
+56,450
New +$838K 0.01% 958
2024
Q2 		– Sell
-21,573
Closed -$324K – 2291
2024
Q1 		$324K Sell
21,573
-11,747
-35% -$192K 0.01% 1413
2023
Q4 		$500K Buy
33,320
+3,720
+13% +$48.3K 0.02% 1067
2023
Q3 		$415K Buy
+29,600
New +$475K 0.02% 1114
2021
Q4 		– Sell
-10,500
Closed -$177K – 1738
2021
Q3 		$177K Buy
+10,500
New +$166K 0.01% 894

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Jump Financial's URGN Position: Q1 2026 in Review

Jump Financial sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 17,900 shares — an estimated $419K sold.

Jump Financial first reported a position in URGN in Q3 2021 and held it in 8 quarters. The position peaked at $2.07M in Q3 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Jump Financial reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
  • Jump Financial sold 17,900 UroGen Pharma shares in Q1 2026, an estimated $419K.
  • Jump Financial first reported a position in UroGen Pharma in Q3 2021 and held it in 8 quarters.
  • Jump Financial's UroGen Pharma position peaked at $2.07M in Q3 2025.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.